All hedge funds or institutions that manage over $100M are required by the SEC to file quarterly reports on their holdings.
These reports are called 13F reports. However, the filings are required
the following quarter
from the reporting period,
which means that by the time the filing is made (and we see them), the information could be five months old.
For funds
with long term positions that make few trades, the holdings might closely resemble their current holdings, even after several months. However, for funds that have high turnover,
the holdings data we see might differ significantly from their current holdings. Institutions are required to report CALL and PUT options, and those positions
are identified in the table. However, they are not required to report short positions.
Click the link icon to see the full transaction history.
Upgrade
to unlock premium data and export to Excel
.
Security |
Imputed Share Price |
Prev Shares |
Current Shares |
Change (Percent) |
Prev Value (USD x1000) |
Current Value (USD x1000) |
Change (Percent) |
SRPT / Sarepta Therapeutics, Inc.
|
|
|
|
|
|
|
|
VINC / Vincerx Pharma, Inc.
|
|
|
|
|
|
|
|
GBT / Global Blood Therapeutics Inc.
|
|
|
|
|
|
|
|
PLRX / Pliant Therapeutics, Inc.
|
|
|
|
|
|
|
|
RETA / Reata Pharmaceuticals Inc - Class A
|
|
|
|
|
|
|
|
XFOR / X4 Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
US74257L1089 / Principia Biopharma Inc.
|
|
|
|
|
|
|
|
FUSN / Fusion Pharmaceuticals Inc.
|
|
|
|
|
|
|
|
STRO / Sutro Biopharma, Inc.
|
|
|
|
|
|
|
|
IMVT / Immunovant, Inc.
|
|
|
|
|
|
|
|
BNTX / BioNTech SE - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
CALT / Calliditas Therapeutics AB (publ) - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
INBX / Inhibrx Biosciences, Inc.
|
|
|
|
|
|
|
|
OM / Outset Medical, Inc.
|
|
|
|
|
|
|
|
TNGX / Tango Therapeutics, Inc.
|
|
|
|
|
|
|
|
NUVB / Nuvation Bio Inc.
|
|
|
|
|
|
|
|
KALV / KalVista Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
NKTX / Nkarta, Inc.
|
|
|
|
|
|
|
|
AFIB / Acutus Medical, Inc.
|
|
|
|
|
|
|
|
RAPT / RAPT Therapeutics, Inc.
|
|
|
|
|
|
|
|
BDTX / Black Diamond Therapeutics, Inc.
|
|
|
|
|
|
|
|
TGTX / TG Therapeutics, Inc.
|
|
|
|
|
|
|
|
NARI / Inari Medical, Inc.
|
|
|
|
|
|
|
|
KROS / Keros Therapeutics, Inc.
|
|
|
|
|
|
|
|
PMVP / PMV Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
AKUS / Akouos Inc
|
|
|
|
|
|
|
|
NRIX / Nurix Therapeutics, Inc.
|
|
|
|
|
|
|
|
HSAQ / Health Sciences Acquisitions Corp 2
|
|
|
|
|
|
|
|
ARYBU / ARYA Sciences Acquisition Corp II
|
|
|
|
|
|
|
|
110122157 / Bristol Meyers Squibb CVR Exp. 12/31/2020
|
|
|
|
|
|
|
|
SAGE / Sage Therapeutics, Inc.
|
|
|
|
|
|
|
|
FMTX / Forma Therapeutics Holdings Inc
|
|
|
|
|
|
|
|
ITOS / iTeos Therapeutics, Inc.
|
|
|
|
|
|
|
|
RPTX / Repare Therapeutics Inc.
|
|
|
|
|
|
|
|
HRMY / Harmony Biosciences Holdings, Inc.
|
|
|
|
|
|
|
|
RNA / Avidity Biosciences, Inc.
|
|
|
|
|
|
|
|
RLAY / Relay Therapeutics, Inc.
|
|
|
|
|
|
|
|
APLT / Applied Therapeutics, Inc.
|
|
|
|
|
|
|
|
LUMO / Lumos Pharma, Inc.
|
|
|
|
|
|
|
|
BTAI / BioXcel Therapeutics, Inc.
|
|
|
|
|
|
|
|
CMPS / COMPASS Pathways plc - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
GMTX / Gemini Therapeutics Inc
|
|
|
|
|
|
|
|
CLDX / Celldex Therapeutics, Inc.
|
|
|
|
|
|
|
|
CYTK / Cytokinetics, Incorporated
|
|
|
|
|
|
|
|
CHAQ.U / Chardan Healthcare Acquisition 2 Corp. Units, each consisting of one share of , and one
|
|
|
|
|
|
|
|
ATHA / Athira Pharma, Inc.
|
|
|
|
|
|
|
|
/ Pandion Therapeutics Inc
|
|
|
|
|
|
|
|
/ Therapeutics Acquisition Corp. Class A
|
|
|
|
|
|
|
|
KYMR / Kymera Therapeutics, Inc.
|
|
|
|
|
|
|
|
ALXO / ALX Oncology Holdings Inc.
|
|
|
|
|
|
|
|
DYNE / Dyntek Inc
|
|
|
|
|
|
|
|
PASG / Passage Bio, Inc.
|
|
|
|
|
|
|
|
ARNA / Arena Pharmaceuticals Inc
|
|
|
|
|
|
|
|
COGT / Cogent Biosciences, Inc.
|
|
|
|
|
|
|
|
LRMR / Larimar Therapeutics, Inc.
|
|
|
|
|
|
|
|
ANNX / Annexon, Inc.
|
|
|
|
|
|
|
|